drugset / Trial / NCT00879749

Safety Study of Nexvax2 in Subjects With Coeliac Disease

NCT00879749 ↗

Phase 1 Completed 34 enrolled Nexpep Pty Ltd
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The main purpose of this study is to determine the safety of weekly injections of Nexvax2 given for three weeks to patients with coeliac disease who have been on a gluten-free diet. The second purpose of this study is to compare the immune response over the three week study period in coeliac disease patients given Nexvax2 compared to those given saline.

Timeline

Start
2009-04
Primary completion
2010-03
Completion
2010-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Nexvax2 Peptide 9 ug Other
Subject Nexvax2 Peptide 30 ug Other
Subject Nexvax2 Peptide 60 ug Other
Subject Nexvax2 Peptide 90 ug Other
Subject Nexvax2 Peptide 900 ug Other

Indications